Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership.
Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin (based in Massachusetts) has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series discovered at the Broad Institute of MIT & Harvard.
By applying knowledge and research into epigenetics, Rodin is now working on neurological diseases, such as Alzheimer’s disease. You can also read our review on 2015’s major developments in the Neurodegenerative disease field.
Rodin and Biogen have now entered into a multi-year research collaboration, in addition to Rodin’s already existing collaborations with the co-founding structure-accelerated lead discovery partner Proteros Biostructures, and then the Alzheimer’s Drug Discovery Foundation.